BriaCell Therapeutics (BCT.TO), which at last look was down 3.8% in U.S. pre-market trading, has received Data Safety Monitoring Board (DSMB) approval to continue with the Phase 3 study of Bria-IMT plus immune checkpoint inhibitor in patients with metastatic breast cancer, the company said on Tuesday,
The recommendation, the sixth, from the board, follows a review of safety data from BriaCell's Phase 3 study, which is being conducted under Fast Track designation granted by the Food and Drug Administration, a statement said.
BriaCell shares were last seen down US$0.13, to US$3.36 in New York trading.